SCHEMBL5000637

SCHEMBL5000637

CC(C)(C)NS(=O)(=O)c1cccc2cnccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 6/20 0.63
PRKCG P05129 6/20 0.63
PRKCB P05771 6/20 0.63
PRKCA P17252 6/20 0.63
PRKCH P24723 6/20 0.63
PRKCI P41743 6/20 0.63
PRKCE Q02156 6/20 0.63
PRKCQ Q04759 6/20 0.63
PRKCZ Q05513 6/20 0.63
PRKCD Q05655 6/20 0.63
PRKD1 Q15139 6/20 0.63
CYP3A4 P08684 5/20 0.63
CYP2D6 P10635 4/20 0.63
NFKB1 P19838 3/20 0.63
GLA P06280 1/20 0.63
LMNA P02545 2/20 0.61
PMP22 Q01453 1/20 0.61
PRKACA P17612 4/20 0.60
PRKACG P22612 4/20 0.60
PRKACB P22694 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10978592 0.84 PRKCG (0.70) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL7481978 0.81 PRKCG (0.68) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL9541267 0.81 PRKD3 (0.61) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10983368 0.81 PRKCG (0.73) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL3577992 0.80 NSD2 (0.65) CYP3A4LMNAMEN1KMT2ASMN1; SMN2
SCHEMBL9541290 0.80 PRKCG (0.86) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL8771380 0.80 CYP3A4 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10981545 0.79 PRKCG (0.74) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL13677595 0.79 CYP3A4 (0.58) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10554867 0.79 PRKD3 (0.53) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414063-B2 Inhibitors of Akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-08-19 US disclosed
US-20070043040-A1 Inhibitors of akt (protein kinase b) ELI LILLY AND COMPANY 2007-02-22 US disclosed
CN-1768040-A Isoquinoline-5-sulfonic acid amides as inhibitors of AKT (protein kinase B) LILLY CO ELI (US) 2006-05-03 CN disclosed
EP-1611105-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2006-01-04 EP disclosed
WO-2004094386-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043040-A1 Inhibitors of akt (protein kinase b) AKT1, AKT2, BRAF PRKD3 353/4885PRKCG 288/4885PRKCB 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.